Travere Therapeutics (TVTX) Common Equity (2011 - 2026)

Travere Therapeutics' Common Equity history runs 16 years deep, the most recent figure standing at $98.7 million for Q1 2026.

• Quarterly Common Equity rose 200.79% year-over-year to $98.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $98.7 million (up 200.79% YoY) and the FY2025 annual result came in at $114.8 million, up 94.37% from the prior year.
• Common Equity was $98.7 million for Q1 2026 at Travere Therapeutics, down from $114.8 million in the prior quarter.
• Across five years, Common Equity topped out at $279.8 million in Q3 2023 and bottomed at -$30.5 million in Q3 2024.
• A 5-year average of $103.8 million and a median of $98.7 million in 2026 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2023 — Common Equity jumped 368.62% — and 2024, when it plunged 110.89%.
• Travere Therapeutics' Common Equity stood at $42.9 million in 2022, then jumped by 368.62% to $200.8 million in 2023, then plunged by 70.58% to $59.1 million in 2024, then jumped by 94.37% to $114.8 million in 2025, then retreated by 14.02% to $98.7 million in 2026.
• Business Quant data shows TVTX's Common Equity at $98.7 million in Q1 2026, $114.8 million in Q4 2025, and $73.6 million in Q3 2025.